Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Ch...(ed onits in-house discovery research. .....),Health
ed on its in-house discovery research.
Safe Harbor
This press release contains plans, intentions, objectives, estimates and expectations that constitute forward-looking statements about Replidyne, Inc. that involve significant risks and uncertainties. Actual results could differ materially from those discussed due to a number of factors including, the success and timing of pre-clinical studies and clinical trials; the Company's ability to obtain a new partner for faropenem on acceptable terms; the Company's ability to obtain and maintain regulatory approval of product candidates and the labeling under any approval that may be obtained; plans to develop and commercialize product candidates; the loss of key scientific or management personnel; the size and growth of the potential markets for the Company's product candidates and the Company's ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of Company estimates regarding expenses, future revenues and capital requirements; the Company's ability to obtain and maintain intellectual property protection for our product candidates; the successful development of the Company's sales and marketing capabilities; the success of competing drugs that are or become available; and the performance of third party manufacturers. These and additional risks and uncertainties are described more fully in the Company's most recent Form 10-Q filed with the SEC under the Securities Exchange Act of 1934. Copies of filings made with the SEC are available through the SEC's electronic data gather analysis and retrieval system (EDGAR) at http://www.sec.gov. All forward-looking statements made in the press release are made as of the date hereof and the Company assumes no obligation to update the forward-looking statements in the document.
'/>"/>
| SOURCE Replidyne, Inc. Copyright©2007 PR Newswire. All rights reserved |
Related medicine news :
1. Replidyne Announces Positive Phase I Results for Topical Antibiotic REP8839
2. $30 M Aid in the pipeline by WB for bird flu in Turkey
3. AEternas acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy
4. Battery power from viruses in the pipeline
5. Effective Vaccine for Leishmaniasis in the Pipeline
6. Home Test Kit for AIDS in the Pipeline
7. Sensing Devices to Measure Sleep In the Pipeline
8. Blood Fluke Vaccine in the Pipeline
9. Chlamydial Vaccine for Humans in the Pipeline
10. New Treatment Option in the Pipeline for Those Suffering From Lung Cancers
11. Treatment of Endometriosis in the Pipeline
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |